Harbor Investment Advisory LLC Sells 2,521 Shares of Johnson & Johnson (NYSE:JNJ)

Harbor Investment Advisory LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 5.1% during the 4th quarter, HoldingsChannel reports. The firm owned 46,835 shares of the company’s stock after selling 2,521 shares during the quarter. Johnson & Johnson makes up approximately 0.6% of Harbor Investment Advisory LLC’s holdings, making the stock its 28th biggest holding. Harbor Investment Advisory LLC’s holdings in Johnson & Johnson were worth $6,773,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of JNJ. International Assets Investment Management LLC grew its stake in shares of Johnson & Johnson by 20,130.0% in the 3rd quarter. International Assets Investment Management LLC now owns 3,454,473 shares of the company’s stock valued at $559,832,000 after purchasing an additional 3,437,397 shares during the period. Janus Henderson Group PLC grew its stake in shares of Johnson & Johnson by 228.1% in the 3rd quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock valued at $549,223,000 after purchasing an additional 2,356,359 shares during the period. Franklin Resources Inc. grew its stake in shares of Johnson & Johnson by 11.4% in the 3rd quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock valued at $2,721,355,000 after purchasing an additional 1,729,281 shares during the period. Holocene Advisors LP bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $225,040,000. Finally, FMR LLC boosted its holdings in shares of Johnson & Johnson by 7.4% in the 3rd quarter. FMR LLC now owns 18,316,920 shares of the company’s stock worth $2,968,440,000 after acquiring an additional 1,265,748 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $145.39 on Thursday. The firm has a fifty day moving average of $148.26 and a two-hundred day moving average of $156.12. The stock has a market capitalization of $350.04 billion, a price-to-earnings ratio of 21.04, a PEG ratio of 2.50 and a beta of 0.51. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22,438,500 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.29 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 9.95 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.41%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. 0.16% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on JNJ. Morgan Stanley boosted their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Royal Bank of Canada boosted their target price on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Wolfe Research began coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Finally, Barclays reduced their target price on Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating on the stock in a report on Tuesday. Eight analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Hold” and a consensus price target of $173.27.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.